Radiotherapy for small-cell lung cancer-Where are we heading?

被引：33

作者：

Bayman, N. A. ^{[1
]}

Sheikh, H. ^{[1
]}

Kularatne, B. ^{[2
]}

Lorigan, P. ^{[2
]}

Blackhall, F. ^{[2
]}

Thatcher, N. ^{[2
]}

Faivre-Finn, C. ^{[1
]}

机构：

[1] Christie Hosp NHS Fdn Trust, Dept Clin Oncol, Manchester M20 4BX, Lancs, England

[2] Christie Hosp NHS Fdn Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England

来源：

LUNG CANCER | 2009年 / 63卷 / 03期

关键词：

Small-cell lung cancer; Radiotherapy; Thoracic radiotherapy; Fractionation; Prophylactic cranial irradiation; Review; THORACIC RADIATION-THERAPY; COMBINED-MODALITY TREATMENT; PHASE-III TRIAL; PROPHYLACTIC CRANIAL IRRADIATION; LEUKEMIA GROUP-B; LIMITED-STAGE; CONCURRENT CHEMOTHERAPY; CHEST RADIOTHERAPY; RANDOMIZED-TRIAL; PROGNOSTIC-FACTORS;

D O I：

10.1016/j.lungcan.2008.06.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Radiotherapy has an established role in the management of limited-disease small-cell lung cancer. However, essential questions related to the optimisation of thoracic radiotherapy remain unanswered including (i) optimal total dose, (ii) fractionation, (iii) timing and sequencing of radiation, (iv) volume of irradiation, and (v) concurrent chemotherapy combinations. The role of thoracic radiotherapy for extensive-disease small-cell lung cancer is more poorly understood but evidence suggests radiotherapy may have an important role in this setting. This review highlights the need for well-designed multi-national trials aimed at the optimisation and standardisation of radiotherapy for SCLC. (c) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：307 / 314

页数：8

共 81 条

[11]

CARNEY DN, 1983, CANCER RES, V43, P2806

[12]

Castellano D, 2006, J CLIN ONCOL, V24, p385S

[13] IMPORTANCE OF RADIATION-DOSE IN ACHIEVING IMPROVED LOCO-REGIONAL TUMOR-CONTROL IN LIMITED STAGE SMALL-CELL LUNG-CARCINOMA - AN UPDATE [J].

CHOI, NC ;

CAREY, RW .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 17 (02) :307-310

[14] Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer [J].

Choi, NC ;

Herndon, JE ;

Rosenman, J ;

Carey, RW ;

Chung, CT ;

Bernard, S ;

Leone, L ;

Seagren, S ;

Green, M .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3528-3536

[15] THE EFFECT OF DOSE OF THORACIC IRRADIATION ON RECURRENCE IN PATIENTS WITH LIMITED STAGE SMALL CELL LUNG-CANCER - INITIAL RESULTS OF A CANADIAN MULTICENTER RANDOMIZED TRIAL [J].

COY, P ;

HODSON, I ;

PAYNE, DG ;

EVANS, WK ;

FELD, R ;

MACDONALD, AS ;

OSOBA, D ;

PATER, JL .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 14 (02) :219-226

[16]

Curran W J Jr, 2001, Cancer Treat Res, V105, P229

[17] Combined-modality therapy for limited-stage small cell lung cancer [J].

Curran, WJ .

SEMINARS IN ONCOLOGY, 2001, 28 (02) :14-22

[18] Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer [J].

De Ruysscher, D ;

Pijls-Johannesma, M ;

Vansteenkiste, J ;

Kester, A ;

Rutten, I ;

Lambin, P .

ANNALS OF ONCOLOGY, 2006, 17 (04) :543-552

[19] Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].

De Ruysscher, D ;

Pijls-Johannesma, M ;

Bentzen, SM ;

Minken, A ;

Wanders, R ;

Lutgens, L ;

Hochstenbag, M ;

Boersma, L ;

Wouters, B ;

Lammering, G ;

Vansteenkiste, J ;

Lambin, P .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063

[20] Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects [J].

De Ruysscher, D ;

Vansteenkiste, J .

RADIOTHERAPY AND ONCOLOGY, 2000, 55 (01) :1-9

← 1 2 3 4 5 6 7 8 9 →